ATE347904T1 - Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert - Google Patents

Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert

Info

Publication number
ATE347904T1
ATE347904T1 AT99956777T AT99956777T ATE347904T1 AT E347904 T1 ATE347904 T1 AT E347904T1 AT 99956777 T AT99956777 T AT 99956777T AT 99956777 T AT99956777 T AT 99956777T AT E347904 T1 ATE347904 T1 AT E347904T1
Authority
AT
Austria
Prior art keywords
associated antigens
cancer
universal tumor
antigens including
htert
Prior art date
Application number
AT99956777T
Other languages
English (en)
Inventor
Lee M Nadler
William C Hahn
Joachim L Schultze
Robert H Vonderheide
Original Assignee
Dana Farber Cancer Inst Inc
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22309530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE347904(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Inst Inc, Whitehead Biomedical Inst filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE347904T1 publication Critical patent/ATE347904T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT99956777T 1998-10-29 1999-10-29 Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert ATE347904T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10610698P 1998-10-29 1998-10-29

Publications (1)

Publication Number Publication Date
ATE347904T1 true ATE347904T1 (de) 2007-01-15

Family

ID=22309530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99956777T ATE347904T1 (de) 1998-10-29 1999-10-29 Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert

Country Status (7)

Country Link
US (1) US7851591B1 (de)
EP (1) EP1126872B1 (de)
AT (1) ATE347904T1 (de)
AU (1) AU1331100A (de)
CA (1) CA2344972A1 (de)
DE (1) DE69934426T2 (de)
WO (1) WO2000025813A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
CA2368967A1 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
EP1241945A4 (de) * 1999-11-15 2005-08-17 Dana Farber Cancer Inst Inc Krebs immunotherapie und diagnose unter verwendung von cytochrom p450
AU2001241533A1 (en) 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
US7385023B1 (en) 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
CN1306027C (zh) * 2002-12-12 2007-03-21 中国医学科学院基础医学研究所 一种体外扩增γδT淋巴细胞的方法
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP2226332A1 (de) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium-tuberculosis-Epitope und Verfahren zu deren Verwendung
WO2009125394A1 (en) 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
RU2581800C2 (ru) 2010-02-16 2016-04-20 Ультимовакс Ас Полипептиды
EP2388014A1 (de) * 2010-05-21 2011-11-23 Dorkoosh, Farid Abedin Therapeutische Anwendung von tumoralen Peptiden mit variabler Immunoglobulinregion bei Patienten mit B-Zell-Malignomen
US9499855B2 (en) * 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
EP3294324A1 (de) 2015-05-13 2018-03-21 Agenus Inc. Impfstoffe zur behandlung und prävention von krebs
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
AU2017336088B2 (en) 2016-09-30 2023-07-06 Inovio Pharmaceuticals, Inc. Tert immunogenic compositions and methods of treatment using the same
EP3784688A2 (de) 2018-04-26 2021-03-03 Agenus Inc. Hitzeschockproteinbindende peptidzusammensetzungen und verfahren zu deren verwendung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5686068A (en) 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US5747317A (en) * 1996-07-08 1998-05-05 Tularik Inc. Human telomerase RNA interacting protein gene
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
WO1998037181A2 (en) 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
AU3456099A (en) * 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase

Also Published As

Publication number Publication date
DE69934426T2 (de) 2007-10-04
DE69934426D1 (de) 2007-01-25
EP1126872A4 (de) 2003-01-02
CA2344972A1 (en) 2000-05-11
EP1126872B1 (de) 2006-12-13
AU1331100A (en) 2000-05-22
US7851591B1 (en) 2010-12-14
EP1126872A1 (de) 2001-08-29
WO2000025813A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
EP1126872A4 (de) KREBSIMMUNTHERAPIE UND KREBSDIAGNOSE UNTER VERWENDUNG UNIVERSELLER TUMORASSOZIIERTER ANTIGEN EINSCHLIESSLICH hERT
DK1349870T3 (da) Sammensætninger til terapien og diagnosen af ovariecancer
WO1999004265A8 (en) Cancer associated nucleic acids and polypeptides
EP1187591A4 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
SI2345671T1 (sl) Optimizirane Fc-variante in postopki za njihovo izdelavo
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
MXPA05014016A (es) Proteinas portadoras para vacunas.
DE69924826T8 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
DK0948518T3 (da) Isoleret nucleinsyremolekyle kodende for et cancer-associeret antigen, selve antigenet samt anvendelser deraf
TR200102191T2 (tr) HER-2/neu füzyon proteinleri.
CY1110695T1 (el) Μεθοδοι για την δημιουργια υψηλου τιτλου ανευ-βοηθου παρασκευασματων απελευθερωμενων ανασυνδυασμενων aav φορεων
MY150237A (en) Cripto blocking antibodies and uses thereof
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
NO992916D0 (no) Fosfodiesterase 8A
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
ATE331791T1 (de) Phosphodiesterase 10
IL139852A0 (en) Monoclonal antibodies directed against the g3bp protein, and uses
WO1999067384A3 (en) Prostate cancer-associated genes
EP1230932A3 (de) Verwendung von Antikörpern zur Vakzinierung gegen Krebs
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
UY26170A1 (es) Antigeno (c42) asociados a tumores

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties